Guided Therapeutics Inc SEC filings GTHP

Guided Therapeutics Inc has 1,000 filings in SEC EDGAR's recent list, going back to Apr 14, 2004. Its latest annual report, Form 10-K, was filed on Mar 31, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 13, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Mar 10, 2026 (material agreement, unregistered share sale, other events). The company's fiscal year ends on December 31.

Guided Therapeutics Inc SEC filings
Form Description Filed Period
4 Insider transaction Oct 27, 2026 Sep 30, 2026
10-Q Quarterly report Aug 13, 2026 Jun 30, 2026
10-Q Quarterly report May 15, 2026 Mar 31, 2026
4 Insider transaction May 5, 2026 Feb 25, 2026
4 Insider transaction Apr 7, 2026 Mar 10, 2026
4 Insider transaction Apr 7, 2026 Mar 10, 2026
4 Insider transaction Apr 7, 2026 Mar 10, 2026
10-K Annual report Mar 31, 2026 Dec 31, 2025
4 Insider transaction Mar 12, 2026 Dec 18, 2025
8-K Current report
Material agreement, Unregistered share sale, Other events
Mar 10, 2026 Mar 2, 2026
4 Insider transaction Mar 4, 2026 Feb 25, 2026
10-Q Quarterly report Nov 13, 2025 Sep 30, 2025
4 Insider transaction Sep 5, 2025 Aug 21, 2025
4 Insider transaction Sep 5, 2025 Aug 21, 2025
4 Insider transaction Sep 5, 2025 Apr 10, 2025
4 Insider transaction Sep 5, 2025 Aug 29, 2025
10-Q Quarterly report Aug 14, 2025 Jun 30, 2025
4 Insider transaction Jun 13, 2025 Jun 3, 2025
4 Insider transaction Jun 12, 2025 Jun 3, 2025
4 Insider transaction Jun 12, 2025 Jun 3, 2025
4/A Form 4 a May 23, 2025 Mar 6, 2025
10-Q Quarterly report May 15, 2025 Mar 31, 2025
4 Insider transaction Apr 17, 2025 Mar 6, 2025
4 Insider transaction Apr 8, 2025 Mar 18, 2025
10-K Annual report Mar 31, 2025 Dec 31, 2024
4 Insider transaction Feb 18, 2025 Jan 17, 2025
8-K Current report
Material agreement
Dec 23, 2024 Dec 18, 2024
4 Insider transaction Dec 20, 2024 Dec 18, 2024
SCHEDULE 13G/A Amended ownership over 5% (passive) Nov 14, 2024 —
10-Q Quarterly report Nov 14, 2024 Sep 30, 2024
4 Insider transaction Oct 25, 2024 Oct 15, 2024
4 Insider transaction Oct 24, 2024 Sep 1, 2024
4 Insider transaction Oct 2, 2024 Sep 23, 2024
8-K Current report
Material agreement
Sep 27, 2024 Sep 23, 2024
4 Insider transaction Sep 9, 2024 Jul 9, 2024
4 Insider transaction Sep 6, 2024 Jul 9, 2024
4 Insider transaction Sep 4, 2024 Jul 9, 2024
4 Insider transaction Sep 3, 2024 Jul 9, 2024
4 Insider transaction Aug 23, 2024 Aug 21, 2024
4 Insider transaction Aug 22, 2024 Aug 21, 2024
4 Insider transaction Aug 22, 2024 Aug 21, 2024
10-Q Quarterly report Aug 14, 2024 Jun 30, 2024
4 Insider transaction Aug 1, 2024 Jul 15, 2024
10-Q Quarterly report May 14, 2024 Mar 31, 2024
4 Insider transaction Apr 19, 2024 Mar 26, 2024
4 Insider transaction Apr 5, 2024 Mar 26, 2024
10-K Annual report Mar 28, 2024 Dec 31, 2023
4 Insider transaction Mar 22, 2024 Mar 1, 2024
4 Insider transaction Feb 22, 2024 Oct 16, 2023
SC 13G/A Amended ownership over 5% (passive) Feb 20, 2024 —
SC 13G/A Amended ownership over 5% (passive) Feb 14, 2024 —
4 Insider transaction Dec 8, 2023 Nov 16, 2023
10-Q Quarterly report Nov 13, 2023 Sep 30, 2023
4 Insider transaction Sep 20, 2023 Aug 21, 2023
4 Insider transaction Sep 11, 2023 Aug 21, 2023
4 Insider transaction Sep 7, 2023 Jul 17, 2023
10-Q Quarterly report Aug 10, 2023 Jun 30, 2023
4 Insider transaction Jun 27, 2023 Feb 23, 2023
4 Insider transaction Jun 27, 2023 Feb 10, 2023
4 Insider transaction Jun 27, 2023 Dec 1, 2022
4 Insider transaction Jun 27, 2023 Sep 1, 2022
4 Insider transaction Jun 26, 2023 Apr 18, 2023
4 Insider transaction Jun 26, 2023 Feb 10, 2023
4 Insider transaction Jun 26, 2023 Sep 1, 2022
3 Initial insider ownership Jun 20, 2023 Mar 7, 2023
4 Insider transaction Jun 2, 2023 Feb 10, 2023
4 Insider transaction Jun 2, 2023 Sep 1, 2022
10-Q Quarterly report May 15, 2023 Mar 31, 2023
10-K Annual report Mar 30, 2023 Dec 31, 2022
8-K Current report
Officer or director change
Mar 9, 2023 Mar 3, 2023
SC 13G/A Amended ownership over 5% (passive) Feb 14, 2023 —
EFFECT Filing Jan 25, 2023 —
CORRESP Letter to the SEC Jan 23, 2023 —
UPLOAD Letter from the SEC Jan 23, 2023 —
S-1 Registration statement Jan 13, 2023 —
RW Filing Dec 2, 2022 —
10-Q Quarterly report Nov 14, 2022 Sep 30, 2022
SC 13G Ownership over 5% (passive) Oct 24, 2022 —
8-K Current report
Material agreement, Unregistered share sale, Other events
Sep 15, 2022 Sep 1, 2022
10-Q Quarterly report Aug 15, 2022 Jun 30, 2022
8-K Current report
Change to shareholder rights, Bylaw or fiscal year change
Jul 29, 2022 Jul 25, 2022
S-1/A Amended registration statement Jul 13, 2022 —
SC 13G Ownership over 5% (passive) Jul 6, 2022 —
S-1/A Amended registration statement Jun 30, 2022 —
10-Q Quarterly report May 16, 2022 Mar 31, 2022
10-K Annual report Mar 30, 2022 Dec 31, 2021
S-1/A Amended registration statement Feb 17, 2022 —
8-K Current report
Change to shareholder rights, Bylaw or fiscal year change
Jan 7, 2022 Jan 6, 2022
10-Q Quarterly report Nov 15, 2021 Sep 30, 2021
S-1/A Amended registration statement Oct 7, 2021 —
S-1 Registration statement Sep 29, 2021 —
8-K Current report
Material agreement, Other events
Sep 7, 2021 Aug 12, 2021
10-Q Quarterly report Aug 18, 2021 Jun 30, 2021
10-Q/A Amended quarterly report Aug 18, 2021 Mar 31, 2021
NT 10-Q Guided therapeutics, inc. Aug 16, 2021 Jun 30, 2021
8-K Current report
Shareholder vote results
Jul 27, 2021 Jul 27, 2021
10-K/A Amended annual report Jul 9, 2021 Dec 31, 2020
8-K Current report
Other events
Jul 7, 2021 Jul 7, 2021
DEF 14A Proxy statement Jul 6, 2021 Jul 2, 2021
PRE 14A Preliminary proxy statement Jun 22, 2021 Jun 22, 2021
8-K Current report
Material agreement, Unregistered share sale, Bylaw or fiscal year change
Jun 10, 2021 Jun 10, 2021
10-Q Quarterly report May 21, 2021 Mar 31, 2021
NT 10-Q Guided therapeutics, inc. May 17, 2021 Mar 31, 2021
10-K Annual report Apr 7, 2021 Dec 31, 2020
NT 10-K Guided therapeutics, inc. Mar 31, 2021 Dec 31, 2020
10-Q/A Amended quarterly report Nov 5, 2020 Sep 30, 2020
10-Q Quarterly report Nov 5, 2020 Sep 30, 2020
EFFECT Filing Oct 15, 2020 —
CORRESP Letter to the SEC Oct 13, 2020 —
S-1/A Amended registration statement Oct 8, 2020 —
8-K Current report
Officer or director change
Sep 16, 2020 Sep 16, 2020
UPLOAD Letter from the SEC Sep 14, 2020 —
S-1 Registration statement Sep 10, 2020 —
10-Q Quarterly report Aug 20, 2020 Jun 30, 2020
NT 10-Q Guided therapeutics, inc. Aug 17, 2020 Jun 30, 2020
10-Q Quarterly report Jul 7, 2020 Mar 31, 2020
NT 10-Q Guided therapeutics, inc. Jun 29, 2020 Mar 31, 2020
8-K Current report
Other events
May 18, 2020 Mar 31, 2020
10-K Annual report Apr 20, 2020 Dec 31, 2019
8-K Current report
Other events
Mar 31, 2020 Mar 31, 2020
10-Q Quarterly report Mar 9, 2020 Sep 30, 2019
10-Q Quarterly report Feb 11, 2020 Jun 30, 2019
NT 10-Q Guided therapeutics, inc. Aug 15, 2019 Jun 30, 2019
10-Q Quarterly report Jul 11, 2019 Mar 31, 2019
NT 10-Q Guided therapeutics, inc. May 15, 2019 Mar 31, 2019
10-K Annual report May 8, 2019 Dec 31, 2018
8-K Current report
Officer or director change
Apr 3, 2019 Apr 3, 2019
NT 10-K Guided therapeutics, inc. Apr 1, 2019 Dec 31, 2018
8-K Current report
Bylaw or fiscal year change
Nov 15, 2018 Nov 14, 2018
10-Q Quarterly report Nov 14, 2018 Sep 30, 2018
8-K Current report
Shareholder vote results
Oct 25, 2018 Oct 25, 2018
DEF 14A Proxy statement Oct 11, 2018 Oct 10, 2018
PRE 14A Preliminary proxy statement Sep 28, 2018 Sep 28, 2018
DEF 14A Proxy statement Sep 17, 2018 Sep 17, 2018
8-K Current report
Material agreement, Unregistered share sale, Bylaw or fiscal year change
Sep 6, 2018 Aug 31, 2018
PRE 14A Preliminary proxy statement Sep 5, 2018 Sep 5, 2018
10-Q Quarterly report Aug 14, 2018 Jun 30, 2018
EFFECT Filing Jul 10, 2018 —
CORRESP Letter to the SEC Jul 9, 2018 —
UPLOAD Letter from the SEC Jul 2, 2018 —
S-1 Registration statement Jun 14, 2018 —
SC 13D Ownership over 5% (active) May 25, 2018 —
3 Initial insider ownership May 25, 2018 Jun 13, 2016
10-Q Quarterly report May 21, 2018 Mar 31, 2018
NT 10-Q Guided therapeutics, inc. May 15, 2018 Mar 31, 2018
10-K/A Amended annual report Apr 20, 2018 Dec 31, 2017
10-K Annual report Apr 17, 2018 Dec 31, 2017
NT 10-K Guided therapeutics, inc. Apr 2, 2018 Dec 31, 2017
10-Q Quarterly report Nov 20, 2017 Sep 30, 2017
NT 10-Q Guided therapeutics, inc. Nov 15, 2017 Sep 30, 2017
8-K/A Amended current report
Material agreement, New debt, Unregistered share sale
Nov 13, 2017 Nov 9, 2017
8-K Current report
Material agreement, New debt, Unregistered share sale
Oct 25, 2017 Oct 25, 2017
RW Guided therapeutics, inc. Sep 25, 2017 —
8-K Current report
Material agreement, New debt, Unregistered share sale
Aug 24, 2017 Aug 24, 2017
10-Q Quarterly report Aug 18, 2017 Jun 30, 2017
8-K/A Amended current report
Material agreement
Aug 17, 2017 Aug 8, 2017
NT 10-Q Filing Aug 15, 2017 Jun 30, 2017
8-K Current report
Material agreement
Aug 14, 2017 Aug 8, 2017
S-1/A Amended registration statement Jun 26, 2017 —
S-1/A Amended registration statement Jun 7, 2017 —
8-K Current report
Material agreement, New debt, Unregistered share sale
May 24, 2017 May 23, 2017
10-Q Quarterly report May 22, 2017 Mar 31, 2017
NT 10-Q Guided therapeutics, inc. May 15, 2017 Mar 31, 2017
S-1/A Amended registration statement Mar 31, 2017 —
424B3 Prospectus Mar 30, 2017 —
8-K Current report
Material agreement
Mar 30, 2017 Mar 30, 2017
424B3 Prospectus Mar 24, 2017 —
8-K/A Amended current report
Material agreement, Unregistered share sale
Mar 24, 2017 Jan 22, 2017
10-K Annual report Mar 22, 2017 Dec 31, 2016
SC 13G Ownership over 5% (passive) Mar 9, 2017 —
424B3 Prospectus Feb 17, 2017 —
8-K Current report
Material agreement, New debt, Unregistered share sale
Feb 17, 2017 Feb 16, 2017
424B3 Prospectus Jan 26, 2017 —
8-K Current report
Material agreement, Unregistered share sale
Jan 26, 2017 Jan 26, 2017
S-1/A Amended registration statement Jan 12, 2017 —
424B3 Prospectus Dec 30, 2016 —
8-K Current report
Material agreement, New debt, Unregistered share sale
Dec 30, 2016 Dec 30, 2016
S-1/A Amended registration statement Dec 9, 2016 —
424B3 Prospectus Dec 8, 2016 —
8-K Current report
Officer or director change
Dec 8, 2016 Dec 8, 2016
424B3 Prospectus Dec 8, 2016 —
8-K Current report
Material agreement
Dec 7, 2016 Dec 7, 2016
424B3 Prospectus Dec 5, 2016 —
10-Q Quarterly report Dec 5, 2016 Sep 30, 2016
3 Initial insider ownership Nov 18, 2016 Nov 14, 2016
424B3 Prospectus Nov 17, 2016 —
8-K Current report
Officer or director change
Nov 17, 2016 Nov 17, 2016
NT 10-Q Guided therapeutics, inc. Nov 15, 2016 Sep 30, 2016
424B3 Prospectus Nov 4, 2016 —
8-K Current report
Material agreement, Other events
Nov 4, 2016 Nov 4, 2016
424B3 Prospectus Sep 23, 2016 —
8-K Current report
Shareholder vote results
Sep 23, 2016 Sep 23, 2016
424B3 Prospectus Sep 9, 2016 —
8-K/A Amended current report
Material agreement, New debt
Sep 9, 2016 Sep 9, 2016
424B3 Prospectus Sep 8, 2016 —
8-K Current report
Material agreement, New debt
Sep 8, 2016 Sep 8, 2016
DEFA14A Additional proxy material Aug 26, 2016 —
DEF 14A Proxy statement Aug 25, 2016 Aug 25, 2016
UPLOAD Letter from the SEC Aug 19, 2016 —
PRER14A Guided therapeutics, inc. Aug 18, 2016 —

Showing 200 filings, the most recent 200. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

Company profile

Industry
Electromedical & Electrotherapeutic Apparatus (SIC 3845)
Listed as
GTHP (OTC)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Peachtree Corners, GA
SEC filer status
Non-accelerated filer, Smaller reporting company
SEC CIK
924515
Former names
SPECTRX INC (until Feb 28, 2008)

Other Electromedical & Electrotherapeutic Apparatus companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.